Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average – Here’s Why

Spero Therapeutics, Inc. (NASDAQ:SPRO) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.06 and traded as low as $0.80. Spero Therapeutics shares last traded at $0.82, with a volume of 436,097 shares traded.

Analyst Ratings Changes

Several equities analysts have recently issued reports on SPRO shares. Evercore ISI lowered Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price target on the stock. in a research note on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a research note on Thursday, January 30th.

Spero Therapeutics Stock Down 1.0 %

The stock has a 50 day moving average price of $0.82 and a two-hundred day moving average price of $1.06. The company has a market cap of $48.52 million, a P/E ratio of 12.72 and a beta of 0.68.

Insider Activity at Spero Therapeutics

In other news, Director Ankit Mahadevia sold 69,219 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $53,990.82. Following the completion of the sale, the director now owns 689,866 shares of the company’s stock, valued at $538,095.48. This trade represents a 9.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Sath Shukla sold 155,333 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $121,159.74. Following the transaction, the chief executive officer now owns 1,736,883 shares in the company, valued at $1,354,768.74. This represents a 8.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 245,241 shares of company stock valued at $191,288 over the last three months. 4.52% of the stock is owned by insiders.

Institutional Investors Weigh In On Spero Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Three Seasons Wealth LLC bought a new stake in shares of Spero Therapeutics in the 4th quarter worth approximately $31,000. XTX Topco Ltd bought a new position in shares of Spero Therapeutics in the fourth quarter worth $31,000. Virtu Financial LLC purchased a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $47,000. Prudential Financial Inc. purchased a new stake in Spero Therapeutics in the fourth quarter valued at approximately $51,000. Finally, Jane Street Group LLC bought a new stake in shares of Spero Therapeutics during the 4th quarter worth $54,000. 25.60% of the stock is owned by hedge funds and other institutional investors.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.